Biomarkers in the Ewing sarcoma family of tumors

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Current Biomarker Findings 2014:4 81–92 Current Biomarker Findings Dovepress

[1]  G. Sauter,et al.  Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. , 2014, International journal of oncology.

[2]  M. Miettinen.  Immunohistochemistry of soft tissue tumours – review with emphasis on 10 markers , 2014, Histopathology.

[3]  J. Xiang,et al.  The clinical and prognostic significance of CCN3 expression in patients with cervical cancer. , 2013, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[4]  Elizabeth T. Wiles,et al.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. , 2013, Genes & cancer.

[5]  Z. Abdullaev,et al.  ERG Expression in Epithelioid Sarcoma: A Diagnostic Pitfall , 2013, The American journal of surgical pathology.

[6]  N. Shukla,et al.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children’s Oncology Group , 2013, Front. Oncol..

[7]  D. Hughes,et al.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression , 2013, Front. Oncol..

[8]  A. Nicholson,et al.  ERBB4 confers metastatic capacity in Ewing sarcoma , 2013, EMBO molecular medicine.

[9]  S. Phillips,et al.  A Decade in Banking Ewing Sarcoma: A Report from the Children’s Oncology Group , 2013, Front. Oncol..

[10]  H. Moch,et al.  The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer , 2013, BMC Cancer.

[11]  J. Neuhaus,et al.  Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. , 2013, Cancer epidemiology.

[12]  A. Llombart‐Bosch,et al.  Superficial small round-cell tumors with special reference to the Ewing's sarcoma family of tumors and the spectrum of differential diagnosis. , 2013, Seminars in diagnostic pathology.

[13]  U. Dirksen,et al.  The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease , 2012, Clinical Sarcoma Research.

[14]  B. Klein,et al.  STEAP1 is overexpressed in cancers: a promising therapeutic target. , 2012, Biochemical and biophysical research communications.

[15]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Blay,et al.  Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. , 2012, European journal of cancer.

[17]  Wei-Lien Wang,et al.  Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma , 2012, Modern Pathology.

[18]  A. Llombart‐Bosch,et al.  Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? , 2012, Virchows Archiv.

[19]  M. Aichler,et al.  High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Llombart‐Bosch,et al.  Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. , 2012, Human pathology.

[21]  Kevin B. Jones,et al.  Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. , 2012, Cancer genetics.

[22]  A. Sherman,et al.  Expression of therapeutic targets in Ewing sarcoma family tumors. , 2012, Human pathology.

[23]  H. Tsuda,et al.  NKX2.2 is a Useful Immunohistochemical Marker for Ewing Sarcoma , 2012, The American journal of surgical pathology.

[24]  Fengli Wang,et al.  The role of PARP1 in the DNA damage response and its application in tumor therapy , 2012, Frontiers of Medicine.

[25]  J. Desai,et al.  Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Sorensen,et al.  The First European Interdisciplinary Ewing Sarcoma Research Summit , 2012, Front. Oncol..

[27]  J. Mora,et al.  Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome , 2012, Pediatric blood & cancer.

[28]  Arul M Chinnaiyan,et al.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.

[29]  O. Delattre,et al.  A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion , 2012, Nature Genetics.

[30]  C. Antonescu,et al.  High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomas , 2012, Genes, chromosomes & cancer.

[31]  U. Dirksen,et al.  The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting , 2012, British Journal of Cancer.

[32]  A. B. Hassan,et al.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma , 2012, Clinical Sarcoma Research.

[33]  David M. Thomas,et al.  Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours , 2012, Clinical Sarcoma Research.

[34]  Helen X. Chen,et al.  Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Sickmann,et al.  STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors , 2011, Molecular Cancer Research.

[36]  A. Llombart‐Bosch,et al.  Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma , 2011, The Journal of pathology.

[37]  A. Llombart‐Bosch,et al.  Epithelial marker expression does not rule out a diagnosis of Ewing’s sarcoma family of tumours , 2011, Virchows Archiv.

[38]  Y. Iwamoto,et al.  Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. , 2011, The American journal of pathology.

[39]  S. Lessnick,et al.  Promiscuous partnerships in Ewing's sarcoma. , 2011, Cancer genetics.

[40]  P. Lollini,et al.  Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling , 2011, Oncogene.

[41]  Gang Han,et al.  Connexin 43 Is a Potential Prognostic Biomarker for Ewing Sarcoma/Primitive Neuroectodermal Tumor , 2011, Sarcoma.

[42]  S. Ferrari,et al.  Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. , 2011, European journal of cancer.

[43]  H. Toledano,et al.  Excellent Prognosis in a Subset of Patients with Ewing Sarcoma Identified at Diagnosis by CD56 Using Flow Cytometry , 2011, Clinical Cancer Research.

[44]  A. Llombart‐Bosch,et al.  Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors , 2011, International journal of cancer.

[45]  A. Paetau,et al.  ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma , 2011, The American journal of surgical pathology.

[46]  Antonio Martínez,et al.  The many faces of atypical Ewing’s sarcoma. A true entity mimicking sarcomas, carcinomas and lymphomas , 2011, Virchows Archiv.

[47]  A. Llombart‐Bosch,et al.  Clinical Significance of Tumor Protein D52 Immunostaining in a Large Series of Ewing's Sarcoma Family of Tumors , 2011, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[48]  M. Schilham,et al.  Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression , 2011, The Journal of pathology.

[49]  D. Parham,et al.  Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour , 2010, Sarcoma.

[50]  C. Paties,et al.  Unusual Myogenic and Melanocytic Differentiation of Soft Tissue pPNETs: An Immunohistochemical and Molecular Study of 3 Cases , 2010, The American journal of surgical pathology.

[51]  A. Llombart‐Bosch,et al.  Histopathological characterization of small cell osteosarcoma with immunohistochemistry and molecular genetic support. A study of 10 cases , 2010, Histopathology.

[52]  S. Navarro,et al.  Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors , 2010, Virchows Archiv.

[53]  S. Strauss,et al.  Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. , 2010, The oncologist.

[54]  M. Colombo,et al.  Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. , 2010, Cancer research.

[55]  Robin L. Jones,et al.  Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma: Twenty Years From the Bench to the Bedside , 2010, Cancer journal.

[56]  U. Dirksen,et al.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Triche,et al.  CD133 expression in chemo-resistant Ewing sarcoma cells , 2010, BMC Cancer.

[58]  N. Marina,et al.  Angiogenesis and vascular targeting in Ewing sarcoma , 2010, Cancer.

[59]  K. Matthay,et al.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow , 2010, Pediatric blood & cancer.

[60]  A. Llombart‐Bosch,et al.  Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support , 2009, Virchows Archiv.

[61]  A. Llombart‐Bosch,et al.  Prognostic relevance of CCN3 in Ewing sarcoma. , 2009, Human pathology.

[62]  U. Dirksen,et al.  Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition , 2009, The Journal of pathology.

[63]  D. Hodgson,et al.  Biomarkers in oncology drug development , 2009, Molecular oncology.

[64]  M. Kauer,et al.  EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. , 2008, Cancer research.

[65]  S. Keir,et al.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[66]  J. Attia,et al.  Prognostic significance of p16INK4a alteration for Ewing sarcoma , 2007, Cancer.

[67]  F. Bertoni,et al.  Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. , 2007, Pathology, research and practice.

[68]  G. Demetri,et al.  Markers of angiogenesis and clinical features in patients with sarcoma , 2007, Cancer.

[69]  J. Goldblum,et al.  Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiation , 2005, Modern Pathology.

[70]  J. Goldblum,et al.  Morphologic and Immunophenotypic Diversity in Ewing Family Tumors: A Study of 66 Genetically Confirmed Cases , 2005, The American journal of surgical pathology.

[71]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  R. Janknecht,et al.  Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing’s Sarcoma , 2004, Clinical Cancer Research.

[73]  D. DeMets,et al.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.

[74]  H. Roberts,et al.  Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. , 2001, Archives of pathology & laboratory medicine.

[75]  A. Llombart‐Bosch,et al.  Immunohistochemical Detection of EWS and FLI-1 Proteins in Ewing Sarcoma and Primitive Neuroectodermal Tumors: Comparative Analysis With CD99 (MIC-2) Expression , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[76]  S. Burchill,et al.  Small Round Cell Tumor with Biphenotypic Differentiation and Variant of t(21;22)(q22;q12) , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[77]  A. Llombart‐Bosch,et al.  Molecular Analysis of the 9p21 Locus and p53 Genes in Ewing Family Tumors , 2001, Laboratory Investigation.

[78]  M. Ladanyi,et al.  Prognostic impact of P53 status in Ewing sarcoma , 2000, Cancer.

[79]  G. Wei,et al.  Prognostic impact of INK4A deletion in Ewing sarcoma , 2000, Cancer.

[80]  Y. Kaneko,et al.  Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. , 2000, Cancer genetics and cytogenetics.

[81]  M. Ladanyi,et al.  Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. , 2000, The American journal of surgical pathology.

[82]  A. Albor,et al.  Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor , 1999, Oncogene.

[83]  P. Pynsent,et al.  Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis , 1999, British Journal of Cancer.

[84]  P. Lollini,et al.  Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. , 1998, Cancer research.

[85]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Kovar,et al.  Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors , 1997, Oncogene.

[87]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[88]  A. Llombart‐Bosch,et al.  Histology, immunohistochemistry, and electron microscopy of small round cell tumors of bone. , 1996, Seminars in diagnostic pathology.

[89]  A. Llombart‐Bosch,et al.  Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. , 1996, Seminars in diagnostic pathology.

[90]  A. Llombart‐Bosch,et al.  Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence , 1995, International journal of cancer.

[91]  P. Sorensen,et al.  Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. , 1995, Cancer research.

[92]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[93]  A. Cabrera,et al.  EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.

[94]  L. Looi,et al.  Cytokeratin immunoreactivity in Ewing sarcoma/ primitive neuroectodermal tumour. , 2013, The Malaysian journal of pathology.

[95]  S. Iacobelli,et al.  Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside‐binding soluble 3 binding protein (LGALS3BP) , 2010, International journal of cancer.

[96]  N. Sato,et al.  Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. , 2008, Oncology reports.

[97]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  T. Triche,et al.  Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? , 1995, European journal of cancer.